Literature DB >> 6214496

Effect of cyclophosphamide on immunological control mechanisms.

J L Turk, D Parker.   

Abstract

Cyclophosphamide (CY) given before immunization causes greatly increased delayed hypersensitivity skin reactions. Increased cell-mediated immunity is associated with depletion of B-lymphocytes from lymphoid tissue and a depression of those lymphocytes whose precursors turn over more rapidly. In the guinea pig, replacement studies showed that the depleted cells were not T-lymphocytes and had immunoglobulin adherent to their surface, a characteristic of B-lymphocytes. Delayed hypersensitivity reactions increased by CY include chemical contact sensitivity, the tuberculin reaction, delayed hypersensitivity to tularemia vaccine and the Jones-Mote reaction to soluble protein antigens. Pretreatment with CY can also increase the antibody response to some antigens, but depress the response to others. In addition, CY has been found to reverse immunological tolerance where this form of unresponsiveness is due to suppressor cells. CY can also enhance the immune response following depression by antigenic competition or desensitization. Other drugs with a similar, but lesser, effect include melphalan, azathioprine and methotrexate.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6214496     DOI: 10.1111/j.1600-065x.1982.tb00429.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  35 in total

1.  After chemotherapy, functional humoral response capacity is restored before complete restoration of lymphoid compartments.

Authors:  A Zandvoort; M E Lodewijk; P A Klok; M A Breukels; G T Rijkers; W Timens
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

2.  Immunotoxicity of immunotherapeutic agents.

Authors:  A G Johnson; J Regal
Journal:  Springer Semin Immunopathol       Date:  1985

3.  Synergistic effects of locally administered cytostatic drugs and a surfactant on the development of delayed-type hypersensitivity to keyhole limpet haemocyanin in mice.

Authors:  J Limpens; R J Scheper
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

4.  Cell-mediated immunity is enhanced by cytostatic drugs continuously released at the site of antigenic stimulation.

Authors:  A M Claessen; H Valster; H Bril; S Meyer; R J Scheper
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Enhancement of interleukin-2 release in rats by treatment with bleomycin and adriamycin in vivo.

Authors:  T A Abdul Hamied; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

6.  Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.

Authors:  Roniel Cabrera; Miguel Ararat; Yiling Xu; Todd Brusko; Clive Wasserfall; Mark A Atkinson; Lung Ji Chang; Chen Liu; David R Nelson
Journal:  Cancer Immunol Immunother       Date:  2012-12-07       Impact factor: 6.968

7.  Herpes simplex virus infection and damage in the central nervous system: immunomodulation with adjuvant, cyclophosphamide and cyclosporin A.

Authors:  S A Bishop; T J Hill
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

8.  Inhibition of contact sensitivity reactions to DNFB by topical cyclosporin application in the guinea-pig.

Authors:  R D Aldridge; A W Thomson; R Rankin; P H Whiting; C Cunningham; J G Simpson
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

9.  Cyclophosphamide treatment antagonizes the in vitro development of Mycobacterium lepraemurium-induced suppressor cell precursors.

Authors:  D Gosselin; R Turcotte; S Lemieux
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

10.  New application of a stabilized active cyclophosphamide derivative (mafosfamide, ASTA Z 7654)--immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug.

Authors:  T Skórski; M Kawalec
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.